Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma
Status:
NOT_YET_RECRUITING
Trial end date:
2026-05-31
Target enrollment:
Participant gender:
Summary
To explore the safety and efficacy of cryoablation combined with PD-1 antibody and bevacizumab for patients with hepatocellular carcinoma resistance to PD-1/L1 antibody.